Method to detect prostate cancer in a sample
First Claim
1. A method for determining a predisposition, or presence of prostate cancer in a patient comprising:
- a) contacting a biological sample of said patient with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide selected from the group consisting of;
i) a polynucleotides according to SEQ ID NOs 9, 10 and 13;
ii) a polynucleotide sequence that hybridizes under high stringency conditions to the polynucleotide sequence in i); and
iii) a polynucleotide sequence fully complementary to i) or ii); and
contacting said biological sample with at least one oligonucleotide that hybridizes with a second prostate specific polynucleotide, b) detecting in said biological sample an amount of PCA3 and second prostate specific polynucleotides; and
comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and therefrom determining the presence or absence of prostate cancer in the biological sample.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to prostate cancer. More specifically, the present invention relates to a method to detect prostate cancer in a patient sample by detecting the RNA encoded by the gene PCA3. More particularly the present invention relates to a method for determining a predisposition, or presence of prostate cancer in a patient comprising: (a) contacting a biological sample of a patient with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting in the biological sample an amount of PCA3 and second prostate specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and therefrom determining the presence or absence of prostate cancer in the biological sample. The present invention further relates to diagnostic kits for the detection of prostate cancer or the risk of developing same in a patient comprising: (a) at least one container means having disposed therein at least one oligonucleotide probe or primer that hybridizes to one a PCA3 nucleic acid or complement thereof; (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid or complement thereof; and (c) reagents enabling a detection of PCA3 and of the second prostate specific nucleic acid when PCA3 or second prostate-specific nucleic acid sequence is present.
-
Citations
40 Claims
-
1. A method for determining a predisposition, or presence of prostate cancer in a patient comprising:
-
a) contacting a biological sample of said patient with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide selected from the group consisting of;
i) a polynucleotides according to SEQ ID NOs 9, 10 and 13;
ii) a polynucleotide sequence that hybridizes under high stringency conditions to the polynucleotide sequence in i); and
iii) a polynucleotide sequence fully complementary to i) or ii); and
contacting said biological sample with at least one oligonucleotide that hybridizes with a second prostate specific polynucleotide,b) detecting in said biological sample an amount of PCA3 and second prostate specific polynucleotides; and
comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and therefrom determining the presence or absence of prostate cancer in the biological sample. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 38, 40)
-
-
30. A diagnostic kit for the detection of prostate cancer or the risk of developing same in a patient comprising:
-
a) at least one container having disposed therein at least one oligonucleotide probe or primer that hybridizes to one of;
i) a PCA3 nucleic acid sequence according to SEQ ID NO;
9, 10 and 13;
ii) a sequence which is fully complementary to i); and
iii) a sequence which hybridizes under high stringency conditions to i) or ii);
b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid or complement thereof; and
c) reagents enabling a detection of PCA3 and of said second prostate specific nucleic acid when said PCA3 or second prostate-specific nucleic acid sequence is present. - View Dependent Claims (31, 32, 33, 34, 35)
-
-
36. A kit for assessing the presence of prostate cancer or the risk of developing same in a patient comprising:
-
a) a first primer pair specific for amplifying a PCA3 nucleic acid associated with prostate cancer present in a patient sample;
b) a second primer pair specific for amplifying a second prostate-specific nucleic acid; and
c) reagents enabling a detection of PCA3 and of said second prostate specific nucleic acid amplification products when said PCA3 or second prostate-specific nucleic acid sequence is present.
-
-
37. A method for detecting prostate cancer in a human patient, comprising:
-
a) performing an in vitro nucleic acid amplification assay on a biological sample of said patient or extract thereof using a first primer pair which is specific to a prostate cancer specific PCA3 sequence and a second primer pair which is specific to a prostate specific nucleic acid sequence; and
b) detecting said PCA3 sequence and said prostate specific nucleic acid sequence, wherein, a detection of said PCA3 nucleic acid sequence or a level thereof correlates with a risk of developing prostate cancer or to a presence of prostate cancer in said patient, and wherein an absence of detection of said PCA3 nucleic acid sequence or lower level thereof in said sample validates an absence of prostate cancer or a lower risk of developing same, when said second prostate specific nucleic acid is detected. - View Dependent Claims (39)
-
Specification